Advertisement

Topics

Selexis SA and OSE Immunotherapeutics SA Company Profile

22:44 EDT 18th June 2019 | BioPortfolio

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies of activation and regulation in immuno-oncology, autoimmune diseases and transplantation. The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical Phase 3 registration trials to R&D:


News Articles [61 Associated News Articles listed on BioPortfolio]

Agenus to use Selexis’ technology to produce therapeutic proteins

Under the new CLAs, Agenus will leverage Selexis’ modular SUREtechnology Platform for the rapid, stable, and cost-effective production of its therapeutic proteins. Selexis licensing and business dev...

Selexis, Teneobio Enter Second Services Agreement

Will utilize Selexis’ SUREtechnology Platform to develop research cell banks for three additional preclinical candidates

Selexis, Turgut Expand Biosimilar Development Pact

Under new commercial license agreements, Selexis will help advance Turgut’s pipeline of biosim products in oncology

Selexis & Agenus Expand CLAs

Agenus will leverage Selexis’ modular SUREtechnology Platform™ for the rapid, stable, and cost-effective production of its therapeutic proteins

Agenus to leverage Selexis' modular SUREtechnology platform for rapid, stable, and cost─effective production of therapeutic proteins

Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, has signed additional commercial license agreements (CLAs) with Agenus Inc, an immuno...

Selexis’ biologic platform generates first-ever approved Soliris biosimilar

First-ever Soliris biosimilar approved in Russia after it was produced through Selexisâ SureTechnology platform and human DNA-derived cell line.

OSE Immunotherapeutics to study cancer drug in France and Belgium

OSE Immunotherapeutics has secured authorisation from the French and Belgian regulatory authorities to conduct a Phase I clinical trial evaluating...Read More... The post OSE Immunotherapeutics to stu...

OSE Immunotherapeutics to Present at Biotech Showcase 2019 Conference

During JP Morgan Healthcare ConferenceSan Francisco, January 7-9, 2019 Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), today announced that Alexis Peyroles, C...

Drugs and Medications [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

The investigators propose to evaluate cabozantinib in combination with durvalumab in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malig...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [34 Associated Companies listed on BioPortfolio]

Selexis SA

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs ...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...

Selexis SA and Berkeley Lights, Inc.

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly d...

Selexis SA and Hoba Therapeutics

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly d...

Selexis SA and TeneoBio, Inc.

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology a...

More Information about "Selexis SA and OSE Immunotherapeutics SA" on BioPortfolio

We have published hundreds of Selexis SA and OSE Immunotherapeutics SA news stories on BioPortfolio along with dozens of Selexis SA and OSE Immunotherapeutics SA Clinical Trials and PubMed Articles about Selexis SA and OSE Immunotherapeutics SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Selexis SA and OSE Immunotherapeutics SA Companies in our database. You can also find out about relevant Selexis SA and OSE Immunotherapeutics SA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record